Irish biotech Ovagen believes study can 'transform' global vaccine manufacture

Groundbreaking study delivered higher virus yield for vaccines

Project director Dr Martin Murphy, Ovagen co-founder and CEO Dr Catherine Caulfield; Dr Leonard Moran, Ovagen co-founder and chair. 

Groundbreaking results achieved by Irish biotech Ovagen Group could "transform the economics of global vaccine manufacturing", the company said on Wednesday.

The company carried out its breakthrough study into yellow fever virus yield. Conducted at the UK's Pirbright Institute, the comparative study showed that Ovagen’s Germ Free embryonated chicken eggs delivered up to 7,600 doses of yellow fever virus per egg compared to just 422 doses per egg using current industry standards.